Table 2

Disclaimer: Early release articles are not considered as final versions. Any changes will be reflected in the online version in the month the article is officially released.

Volume 31, Supplement—October 2025

SUPPLEMENT ISSUE

Persistence of Symptoms among Commercially Insured Patients with Coccidioidomycosis, United States, 2017–2023

Ian Hennessee¹

, Samantha L. Williams, Kaitlin Benedict, Dallas J. Smith, George R. Thompson, and Mitsuru Toda

Author affiliation: Centers for Disease Control and Prevention, Atlanta, Georgia, USA (I. Hennessee, S.L. Williams, K. Benedict, D.J. Smith, M. Toda); University of California, Davis, Sacramento, California, USA (G.R. Thompson III)

Main Article

Prevalence ratios of symptoms among commercially insured patients with coccidioidomycosis during 4 follow-up periods after index date compared with baseline, United States, July 2017‒January 2023*

	0–3 months		3–6 months		6–9 months		9–12 months
Characteristic	PR (95% CI)	p value	PR (95% CI)	p value	PR (95% CI)	p value	PR (95% CI)	p value
Coccidioidomycosis-associated symptoms
Abnormal weight loss	3.64 (2.08–6.82)	<0.001	1.29 (0.64–2.63)	0.5	1.21 (0.60– 2.50)	0.6	1.29 (0.64– 2.63)	0.5
Chest pain	2.10 (1.71–2.60)	<0.001	0.92 (0.71–1.18)	0.5	0.69 (0.53– 0.91)	0.009	0.83 (0.64– 1.07)	0.15
Cough	2.83 (2.48–3.24)	<0.001	1.16 (0.99–1.37)	0.063	0.89 (0.75–1.06)	0.2	0.92 (0.77–1.09)	0.3
Dyspnea	3.05 (2.56–3.67)	<0.001	1.29 (1.05–1.59)	0.018	1.10 (0.89–1.37)	0.4	0.90 (0.72–1.14)	0.4
Erythema nodosum or multiforme	28.6 (6.97–117)	<0.001	5.50 (1.48–35.5)	0.026	2.50 (0.54–17.4)	0.3	1.50 (0.25–11.4)	0.7
Fatigue or malaise	2.48 (2.06–3.00)	<0.001	1.31 (1.06–1.62)	0.012	1.33 (1.08–1.65)	0.008	1.29 (1.04–1.60)	0.019
Fever	3.28 (2.56–4.24)	<0.001	0.88 (0.64–1.22)	0.4	0.67 (0.47–0.95)	0.026	0.76 (0.54– 1.07)	0.12
Generalized hyperhidrosis	4.43 (2.07–10.9)	<0.001	1.57 (0.62– 4.26)	0.3	1.00 (0.34– 2.92)	>0.9	1.00 (0.34– 2.92)	>0.9
Headache	2.55 (1.58–4.24)	<0.001	1.50 (0.88– 2.60)	0.14	1.14 (0.64– 2.03)	0.7	1.82 (1.09– 3.10)	0.024
Myalgia	2.42 (1.27–4.91)	0.010	1.25 (0.59– 2.72)	0.6	1.00 (0.45– 2.25)	>0.9	0.50 (0.17– 1.29)	0.2
Pain in joint	1.28 (1.10–1.50)	0.001	1.19 (1.02– 1.40)	0.027	1.17 (1.00– 1.37)	0.050	1.25 (1.07– 1.46)	0.005
Weakness	2.53 (1.85–3.51)	<0.001	1.49 (1.05– 2.13)	0.026	1.71 (1.22– 2.42)	0.002	1.86 (1.34– 2.62)	<0.001
IACCI symptoms
Depression	1.59 (1.22–2.07)	<0.001	1.17 (0.89–1.56)	0.3	1.18 (0.90–1.57)	0.2	1.15 (0.87–1.53)	0.3
Dizziness	1.73 (1.23–2.47)	0.002	1.10 (0.75–1.62)	0.6	0.96 (0.64–1.43)	0.8	1.37 (0.95–1.98)	0.092
Generalized anxiety disorder	1.26 (0.93–1.74)	0.14	1.18 (0.86–1.62)	0.3	1.32 (0.97–1.81)	0.077	1.32 (0.97–1.81)	0.077
Insomnia	1.60 (1.12–2.30)	0.011	1.13 (0.76–1.67)	0.5	0.98 (0.65–1.47)	>0.9	0.98 (0.65–1.47)	>0.9
Irritable bowel syndrome	1.23 (0.77–1.98)	0.4	0.61 (0.34–1.07)	0.091	0.74 (0.43–1.26)	0.3	0.52 (0.28–0.93)	0.031
Palpitations	1.47 (1.02–2.13)	0.040	0.96 (0.64–1.44)	0.8	0.91 (0.61–1.38)	0.7	0.89 (0.59–1.35)	0.6
Sleep apnea	1.47 (1.23–1.77)	<0.001	1.13 (0.93–1.38)	0.2	1.14 (0.94–1.38)	0.2	1.14 (0.94–1.38)	0.2
Tinnitus	2.56 (1.23–5.82)	0.017	1.33 (0.57–3.26)	0.5	1.33 (0.57–3.26)	0.5	0.89 (0.33–2.32)	0.8

*Baseline was 180–121 days before the index date. The 3-month follow-up periods were nonoverlapping periods after the index date: 0–89 days (0–3 months), 90–179 days (3–6 months), 180–269 days (6–9 months), and 270–365 days (9–12 months). Because of insufficient cell size, prevalence ratios were not calculated for chills, intracranial abscess, meningitis, irritability or anger, general paresis, or hypoactive sexual desire disorder. IACCI, infection-associated chronic conditions and illnesses; PR, prevalence ratio.

Main Article

¹Current affiliation: The Carter Center, Atlanta, Georgia, USA

Page created: September 02, 2025

Page updated: November 14, 2025

Page reviewed: November 14, 2025

The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.